Manufacturer Supply with High Purity and Stable Quality
Lurasidone Hydrochloride (CAS 367514-88-3) Related Intermediates:
(1R,2R)-1,2-Cyclohexanedimethanol CAS 65376-05-8
(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione CAS 14805-29-9
Lurasidone Hydrochloride CAS 367514-88-3 API
High Quality, Commercial Production
| Chemical Name |
(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione |
| Synonyms |
exo-2,3-Norbornanedicarboximide; Lurasidon Hydrochloride Intermediate |
| CAS Number |
14805-29-9 |
| CAT Number |
RF-PI264 |
| Stock Status |
In Stock, Production Scale Up to Tons |
| Molecular Formula |
C9H11NO2 |
| Molecular Weight |
165.19 |
| Density |
1.285 |
| Shipping Condition |
Shipped Under Ambient Temperature as Non-Hazardous Chemical |
| Brand |
Ruifu Chemical |
| Item |
Specifications |
| Appearance |
White to Almost White Powder |
| Melting Point |
150.0~154.0℃ |
| Differentiate |
H-NMR |
| Related Compound |
≤0.50% |
| Endo Isomer |
≤0.15% |
| Water Content |
≤1.0% |
| Purity / Analysis Method |
≥99.0% (HPLC) |
| Test Standard |
Enterprise Standard |
| Usage |
Lurasidon Hydrochloride (CAS 367514-88-3) Intermediate |
Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione (CAS 14805-29-9) with high quality, commercial production.
(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole-1,3(2H)-dione (CAS 14805-29-9) is an intermediate typically in the synthesis of Lurasidon Hydrochloride (CAS 367514-88-3) in the treatment of Schizophrenia.
Lurasidone was approved by the FDA in 2010 for schizophrenia and in 2013 for depressive episodes associated with bipolar disorder. Lurasidone is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD). It received approval by the EMA in 2014 for schizophrenia. Lurasidone has also been launched in a number of countries outside the US and EU, including Canada, where it is approved for both indications. It is produced through a multi-step chemical process.